$ cat ./records/gates-foundation-expands-sayana-press-self-injectable-contracepti-2023.txt
Gates Foundation Expands Sayana Press Self-Injectable Contraceptive to 92 Countries
[RECORD.TXT] · cat --full
The Gates Foundation, Children's Investment Fund Foundation, Pfizer, and Becton Dickinson announced an expansion of their Sayana Press partnership to deliver more than 320 million doses of the self-injectable progestogen-only contraceptive through 2030. Sayana Press uses a uniject device that women can administer themselves without a clinic visit — a critical advantage in regions with few health workers. The agreement expanded eligible countries from 69 to 92, increased manufacturing capacity by 65 percent, and guaranteed a public-sector price of $0.85 per dose, down from an earlier price of $1.00.
Free forever · No ads · Solo developer
If this was worth a read, help make the next entry possible.
Every entry in this archive was researched, verified, and written by one person — for free. No corporate funding. No ad revenue. Just a developer who believes verified history should be accessible to everyone. Your donation directly funds new entries.
Crypto accepted · No subscription required
← Previous
Gates-Backed CEPI Funds Jurata Thin Film for Needle-Free Sublingual mRNA Vaccine Wafer
Next →
Gates Foundation Commits $100 Million to UNFPA Supplies Partnership
[CROSS_REFERENCES] · grep --category='Global Health'
Related Accomplishments
January 2026
Gates-backed World Mosquito Program reaches 16 million people protected from dengue via Wolbachia method
The World Mosquito Program — backed in part by the Gates Foundation — announced in January 2026 that its Wolbachia-infected mosquito releases had reached over 16.1 million people across multiple countries, including Colombia, Indonesia, Brazil, Sri Lanka, Fiji, Vanuatu, and Vietnam. Wolbachia-carrying Aedes aegypti mosquitoes — which block dengue, Zika, chikungunya, and yellow fever transmission — had established self-sustaining populations in treated cities without requiring ongoing releases. Gold-standard randomised trials in Indonesia showed a 77% reduction in dengue incidence. The program represented one of the largest and most cost-effective vector control deployments in history.
2025
Gates-Funded Monoclonal Antibody Shows Early Promise as a Single-Shot Malaria Shield
[ARCHIVE_FUNDING] · INDEPENDENT · NO ADS
One developer. >300 verified entries. Zero ads. Forever free.
No sponsors, no paywall, no algorithm. If this archive has been useful to you, reader support is what keeps it running.